These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 25069659)

  • 21. Low endogenous and chemical induced heat shock protein induction in a 0N3Rtau-expressing Drosophila larval model of Alzheimer's disease.
    Sinadinos C; Quraishe S; Sealey M; Samson PB; Mudher A; Wyttenbach A
    J Alzheimers Dis; 2013; 33(4):1117-33. PubMed ID: 23114515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone.
    Singh JK; Hutt DM; Tait B; Guy NC; Sivils JC; Ortiz NR; Payan AN; Komaragiri SK; Owens JJ; Culbertson D; Blair LJ; Dickey C; Kuo SY; Finley D; Dyson HJ; Cox MB; Chaudhary J; Gestwicki JE; Balch WE
    Cell Chem Biol; 2020 Mar; 27(3):292-305.e6. PubMed ID: 32017918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.
    Dobrowsky RT
    Curr Diab Rep; 2016 Aug; 16(8):71. PubMed ID: 27318486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases.
    Lackie RE; Maciejewski A; Ostapchenko VG; Marques-Lopes J; Choy WY; Duennwald ML; Prado VF; Prado MAM
    Front Neurosci; 2017; 11():254. PubMed ID: 28559789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors.
    Dickey CA; Eriksen J; Kamal A; Burrows F; Kasibhatla S; Eckman CB; Hutton M; Petrucelli L
    Curr Alzheimer Res; 2005 Apr; 2(2):231-8. PubMed ID: 15974923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.
    Bohush A; Bieganowski P; Filipek A
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chaperone signalling complexes in Alzheimer's disease.
    Koren J; Jinwal UK; Lee DC; Jones JR; Shults CL; Johnson AG; Anderson LJ; Dickey CA
    J Cell Mol Med; 2009 Apr; 13(4):619-30. PubMed ID: 19449461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linking HSP90 target occupancy to HSP70 induction and efficacy in mouse brain.
    Thirstrup K; Sotty F; Montezinho LC; Badolo L; Thougaard A; Kristjánsson M; Jensen T; Watson S; Nielsen SM
    Pharmacol Res; 2016 Feb; 104():197-205. PubMed ID: 26731018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.
    Jinwal UK; Koren J; Borysov SI; Schmid AB; Abisambra JF; Blair LJ; Johnson AG; Jones JR; Shults CL; O'Leary JC; Jin Y; Buchner J; Cox MB; Dickey CA
    J Neurosci; 2010 Jan; 30(2):591-9. PubMed ID: 20071522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease.
    Kumar P; Jha NK; Jha SK; Ramani K; Ambasta RK
    J Alzheimers Dis; 2015; 43(2):341-61. PubMed ID: 25096626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
    Lu Y; Ansar S; Michaelis ML; Blagg BS
    Bioorg Med Chem; 2009 Feb; 17(4):1709-15. PubMed ID: 19138859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHIP-ping away at tau.
    Goryunov D; Liem RK
    J Clin Invest; 2007 Mar; 117(3):590-2. PubMed ID: 17332887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.
    Walton-Diaz A; Khan S; Bourboulia D; Trepel JB; Neckers L; Mollapour M
    Future Med Chem; 2013 Jun; 5(9):1059-71. PubMed ID: 23734688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
    Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.
    Miyata Y; Koren J; Kiray J; Dickey CA; Gestwicki JE
    Future Med Chem; 2011 Sep; 3(12):1523-37. PubMed ID: 21882945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tau protein aggregates inhibit the protein-folding and vesicular trafficking arms of the cellular proteostasis network.
    Yu A; Fox SG; Cavallini A; Kerridge C; O'Neill MJ; Wolak J; Bose S; Morimoto RI
    J Biol Chem; 2019 May; 294(19):7917-7930. PubMed ID: 30936201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Thermosensitization of tumor cells with inhibitors of chaperone activity and expression].
    Kudriavtsev VA; Makarova IuM; Kabakav AE
    Biomed Khim; 2012; 58(6):662-72. PubMed ID: 23350198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle.
    Li J; Richter K; Reinstein J; Buchner J
    Nat Struct Mol Biol; 2013 Mar; 20(3):326-31. PubMed ID: 23396352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel C-terminal homologue of Aha1 co-chaperone binds to heat shock protein 90 and stimulates its ATPase activity in Entamoeba histolytica.
    Singh M; Shah V; Tatu U
    J Mol Biol; 2014 Apr; 426(8):1786-98. PubMed ID: 24486610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease.
    Guy NC; Garcia YA; Cox MB
    Curr Mol Pharmacol; 2015; 9(2):109-25. PubMed ID: 25986565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.